Treanda Approved; Cephalon Ready With Tripled Salesforce To Launch In Chronic Lymphocytic Leukemia
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm expects to ship product within 2-3 weeks, Cephalon tells “The Pink Sheet” DAILY.
You may also be interested in...
Eisai Signs Bendamustine Deal With Symbio In Singapore And Korea, Highlighting Asian Oncology Market Potential
Tokyo-based biotech start-up Symbio will grant exclusive development and marketing rights for non-Hodgkin's lymphoma drug bendamustine to Japan's fourth-largest drug maker Eisai in both Korea and Singapore
Cephalon Showcasing Treanda Use For Refractory Indolent NHL At ASH
Cephalon's oncology drug Treanda is getting attention at the 2008 American Society of Hematology annual meeting, where the company is starting to showcase its use in the newest indication - refractory indolent non-Hodgkins lymphoma
Cephalon Showcasing Treanda Use For Refractory Indolent NHL At ASH
Cephalon's oncology drug Treanda is getting attention at the 2008 American Society of Hematology annual meeting, where the company is starting to showcase its use in the newest indication - refractory indolent non-Hodgkins lymphoma